title: Alpha-methyldopa-type autoimmune hemolytic anemia caused by lobenzarit disodium of a mefenamic acid derivative and immunomodulator.
authors.forename: S
authors.initials: S
authors.lastname: Andou
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Harada
authors.forename: J
authors.initials: J
authors.lastname: Ooi
authors.forename: J
authors.initials: J
authors.lastname: Nomiyama
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Ookubo
authors.forename: Y
authors.initials: Y
authors.lastname: Azuno
authors.forename: Y
authors.initials: Y
authors.lastname: Fujii
authors.forename: K
authors.initials: K
authors.lastname: Kaku
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008750:Methyldopa / Q000009:adverse effects*; D008875:Middle Aged; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D062367:ortho-Aminobenzoates; D008750:Methyldopa; C015735:lobenzarit